Express Pharma

JULY 6, 2025

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As biosimilars and generics flood the market, pricing pressures will intensify—particularly in oncology—challenging pharma companies to rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term growth, says GlobalData.

Biosimilars 66

Biosimilars 66

The Guardian - Pharmaceutical Industry

JULY 6, 2025

Testing is difficult for drugs for rare diseases, and new rules may make it harder for sufferers to obtain life-saving drugs US drug regulators have increasingly signaled a focus on faster approvals and rare diseases, but patients with ultra-rare ailments fear they are falling through the cracks, especially given challenges to conducting clinical trials.

81

81

Med Ed 101

JULY 6, 2025

If you’re a pharmacist or pharmacy student looking to test your knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs), we’ve got the perfect brain-teasing activity for you. Introducing our NSAID Crossword Puzzle—a fun, interactive way to review key drug facts while sharpening your clinical memory. You’ll find the answers to our NSAID Crossword Puzzle at the end […] The post Can You Pass?

52

52

Pharmacy Joe

JULY 6, 2025

In this episode, I’ll discuss which overdose patients with prolonged QTc are most likely to experience ventricular dysrhythmia. Episode 1041: Predicting Which Overdose Patients With Prolonged QTc Will Have Ventricular Dysrhythmia Subscribe on iTunes , Android , or Stitcher Among overdose patients who present to the emergency department, those with a severely prolonged QTc of over 500 milliseconds represent a cohort that is at an elevated risk of a poor clinical outcome, such as ventricular dysrh

Inpatient 52

Inpatient Hospitals 52

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

Express Pharma

JULY 6, 2025

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is authorised for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.

Biosimilars 66

Biosimilars 66

Pharmacy Times

JULY 6, 2025

GLP-1 medications like semaglutide face scrutiny over compounded versions, raising concerns about patient safety and counterfeit products in diabetes treatment.

Compounding 26

Compounding Diabetes 26